Low-dose oral etidronate therapy for immobilization hypercalcaemia associated with Guillain-Barré syndrome

Acta Paediatr. 2001 Oct;90(10):1202-4. doi: 10.1080/080352501317061666.

Abstract

A low dose of oral etidronate (3.7 mg kg(-1) d(-1)) was administered for immobilization hypercalcaemia associated with Guillain-Barré syndrome in a 12-y-old boy. There was a slight increase in osteoblastic bone formation reflected by alkaline phosphatase and in particular bone-specific alkaline phosphatase during the treatment and serum calcium decreased to the normal range within 2 wk. No adverse side effects were observed and the patient's linear growth subsequently progressed.

Conclusion: A low dose of oral etidronate is safe and effective for treatment of immobilization hypercalcaemia in children, without inhibiting bone formation.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Child
  • Etidronic Acid / administration & dosage*
  • Guillain-Barre Syndrome / complications*
  • Humans
  • Hypercalcemia / drug therapy*
  • Hypercalcemia / etiology
  • Hypokinesia / complications*
  • Male

Substances

  • Etidronic Acid